-
Electronic (PDF)
-
Site License
-
Enterprisewide
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2012
GlobalData, January 2012, Pages: 157
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2012
Summary
GlobalData's clinical trial report, “Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2012" provides data on the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Keywords
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials, Trial Designs, Subjects Recruited, Unaccomplished Trials of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer , Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas, M.D. Andersons, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, National Cancer Center, University of Pennsylvania.
List of Tables
List of Figures
Introduction
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
Report Guidance
Clinical Trials by Region
Clinical Trials by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by BRIC Nations
Clinical Trials by G7 Nations
Clinical Trials in G7 Nations by Trial Status
Clinical Trials by E7 Nations
Clinical Trials in E7 Nations by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Unaccomplished Trials of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
Subjects Recruited Over a Period of Time
Prominent Sponsors
Top Companies Participating in Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials
Prominent Drug Comparison
Clinical Trial Profiles
Clinical Trial Overview of Top Companies
Algeta ASA
Clinical Trial Overview of Algeta ASA
Bristol-Myers Squibb Company
Clinical Trial Overview of Bristol-Myers Squibb Company
Sanofi
Clinical Trial Overview of Sanofi
Amgen Inc.
Clinical Trial Overview of Amgen Inc.
Johnson & Johnson
Clinical Trial Overview of Johnson & Johnson
Oxford BioMedica plc
Clinical Trial Overview of Oxford BioMedica plc
Exelixis, Inc.
Clinical Trial Overview of Exelixis, Inc.
Astellas Pharma Inc.
Clinical Trial Overview of Astellas Pharma Inc.
Novartis AG
Clinical Trial Overview of Novartis AG
Ascenta Therapeutics, Inc.
Clinical Trial Overview of Ascenta Therapeutics, Inc.
Piedmont Research Center, LLC.
Clinical Trial Overview of Piedmont Research Center, LLC.
EntreMed, Inc.
Clinical Trial Overview of EntreMed, Inc.
Incyte Corporation
Clinical Trial Overview of Incyte Corporation
Celgene Corporation
Clinical Trial Overview of Celgene Corporation
Kaiser Permanente
Clinical Trial Overview of Kaiser Permanente
Novartis Pharma AG
Clinical Trial Overview of Novartis Pharma AG
Enzon Pharmaceuticals, Inc.
Clinical Trial Overview of Enzon Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited
Clinical Trial Overview of Teva Pharmaceutical Industries Limited
Pfizer Inc.
Clinical Trial Overview of Pfizer Inc.
Merck & Co., Inc.
Clinical Trial Overview of Merck & Co., Inc.
Clinical Trial Overview of Top Universities / Institutes / Hospitals
European Organization for Research and Treatment of Cancer
Clinical Trial Overview of European Organization for Research and Treatment of Cancer
Fox Chase Cancer Center
Clinical Trial Overview of Fox Chase Cancer Center
The University of Texas M. D. Anderson Cancer Center
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center
University of California, San Francisco
Clinical Trial Overview of University of California, San Francisco
British Columbia Cancer Agency
Clinical Trial Overview of British Columbia Cancer Agency
Duke University
Clinical Trial Overview of Duke University
Albert Einstein College of Medicine of Yeshiva University
Clinical Trial Overview of Albert Einstein College of Medicine of Yeshiva University
New York University School of Medicine
Clinical Trial Overview of New York University School of Medicine
Alberta Health Services
Clinical Trial Overview of Alberta Health Services
Kurume University
Clinical Trial Overview of Kurume University
Barbara Ann Karmanos Cancer Institute
Clinical Trial Overview of Barbara Ann Karmanos Cancer Institute
Sheba Medical Center
Clinical Trial Overview of Sheba Medical Center
UCSF Helen Diller Family Comprehensive Cancer Center
Clinical Trial Overview of UCSF Helen Diller Family Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center
Clinical Trial Overview of Sidney Kimmel Comprehensive Cancer Center
Dana-Farber Cancer Institute
Clinical Trial Overview of Dana-Farber Cancer Institute
Roswell Park Cancer Institute
Clinical Trial Overview of Roswell Park Cancer Institute
University of Washington
Clinical Trial Overview of University of Washington
Medical University of Vienna
Clinical Trial Overview of Medical University of Vienna
The University of Iowa
Clinical Trial Overview of The University of Iowa
Assistance Publique - Hopitaux de Paris
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris
Five Key Clinical Profiles
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Disclaimer
Source
List of Tables
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Zone, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Top Countries, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, North America, Top Countries, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, BRIC Countries, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, G7 Countries, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, E7 Countries, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Phase, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials In Progress by Phase 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Trial Status, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Withdrawn Clinical Trials, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Terminated Clinical Trials, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2005-2010
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Algeta ASA, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson & Johnson, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Oxford BioMedica plc, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Exelixis, Inc., 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Astellas Pharma Inc., 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Ascenta Therapeutics, Inc., 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Piedmont Research Center, LLC., 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by EntreMed, Inc., 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Incyte Corporation, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Kaiser Permanente, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis Pharma AG, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Enzon Pharmaceuticals, Inc., 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Teva Pharmaceutical Industries Limited, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Fox Chase Cancer Center, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by British Columbia Cancer Agency, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Albert Einstein College of Medicine of Yeshiva University, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by New York University School of Medicine, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Alberta Health Services, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Kurume University, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Barbara Ann Karmanos Cancer Institute, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sheba Medical Center, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by UCSF Helen Diller Family Comprehensive Cancer Center, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sidney Kimmel Comprehensive Cancer Center, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Dana-Farber Cancer Institute, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Roswell Park Cancer Institute, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Washington, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Iowa, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2012-
List of Figures
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Zone (%), 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Top Countries, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, BRIC Countries (%), 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, G7 Countries (%), 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, E7 Countries (%), 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Phase (%), 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials In Progress by Phase, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Trial Status, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2005-2010
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2012-
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2012-
GlobalData Methodology
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
